Navigation Links
Drug may prolong organ life in noncompliant kidney transplant patients
Date:5/30/2008

New research from the University of California, San Diego Department of Medicine, Division of Nephrology, shows that the anti-rejection drug sirolimus (brand name Rapamune) may help prolong the clinical benefit of transplanted kidneys and delay rejection, especially in patients who do not regularly take their prescribed medications (are "non-compliant"). While the transplant field has been highly successful at reducing rejection and graft loss in the first year, post-transplant, reducing risk for graft rejection in the long-term has proved more difficult.

The findings are being presented at the 2008 American Transplant Congress (ATC), in Toronto on Saturday, May 31, 2008, by Cheri Ye, M.D., who was mentored by Robert Steiner, M.D., professor of medicine, and Director of Transplant Nephrology.

"No one is perfect at taking medications," explained Steiner. "But missing doses of immunosuppression, or not taking full doses each day, will bring about gradual rejection of kidney transplants that is almost impossible to detect in its early stages. Long acting drugs like sirolimus may help with this problem."

A team of five UC San Diego investigators reported a careful assessment of immune function at "trough" levels (lowest daily levels) of the three most commonly used immunosuppressive drugs, using an assay (ImmuKnow/ Cylex) designed specifically to measure the degree of immunosuppression at any given time. Lower "mitogenic response" meant better immunosuppression and more protection from rejection. On average, the participants, 160 kidney transplant patients, were 6.4 years out from their transplant.

At these trough levels of drug in the blood stream, the assay demonstrated that sirolimus caused a significantly lower level of mitogenic response, and results appeared to be stable in individual patients over time.

"At least half of transplanted kidneys are lost through chronic graft rejection, usually within 10 years. When patients do not have those rejection problems, they can go for 20 to 30 years before kidney rejection or other serious problems. This is an especially important issue now because of our nationwide donor-organ shortage," said coauthor, David Perkins, M.D., Ph.D., professor of medicine & surgery, and Director of Research for Transplantation.

"This study was not commercially funded," added Steiner. "We just wanted to confirm what we suspected from experience in our transplant clinic, where we focus on compliance in many ways to help our patients keep their kidneys functioning well. We showed that when the daily dose is wearing off and another dose is due to be taken, patients taking sirolimus could be more protected against rejection than other commonly used agents."

The assay used is the only commercially available of its kind, and potentially valuable, but researchers emphasized that experience and understanding of it is limited.

"Our ATC abstract is a report of clinical experience, but real progress is often made at the level of basic science. My laboratory is studying this intensively at a basic level in several ways, including looking at the genetics associated with various responses to the assay," said Perkins.

The researchers believe that this new study may help develop tools to monitor patients in the long-term, and also contribute to a protocol for using sirolimus in less compliant patients. Steiner pointed out that, "The best results will occur if we prevent rejection, because once rejection is established the threat to graft survival is much greater, no matter what we do."


'/>"/>

Contact: Kim Edwards
kedwards@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
2. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
3. Token resuscitation attempts on hopelessly ill patients prolong suffering
4. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
6. Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival
7. Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
8. AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage
9. California Small Business Association Condemns California Nurses Associations Decision to Call Prolonged Strike at Hospitals Throughout Northern California
10. Prolonged Fasting Boosts Risk of Rare Stroke
11. Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: